Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
Shang Su, Zimo Yang, Hongying Gao, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 16, pp. 7575-7582
Open Access | Times Cited: 156

Showing 1-25 of 156 citing articles:

PROTACs: great opportunities for academia and industry
Xiuyun Sun, Hongying Gao, Yiqing Yang, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 513
Cell cycle on the crossroad of tumorigenesis and cancer therapy
Jing Liu, Yunhua Peng, Wenyi Wei
Trends in Cell Biology (2021) Vol. 32, Iss. 1, pp. 30-44
Open Access | Times Cited: 261
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup, Charlene Fallan, Matthias G. J. Baud
Exploration of Targeted Anti-tumor Therapy (2020) Vol. 1, Iss. 5
Open Access | Times Cited: 249
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Simin Qi, Jinyun Dong, Zhiyuan Xu, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 205
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Sajid Khan, Yonghan He, Xuan Zhang, et al.
Oncogene (2020) Vol. 39, Iss. 26, pp. 4909-4924
Open Access | Times Cited: 189
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Xinyi Li, Wenchen Pu, Qingquan Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 187
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 168
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Shenxin Zeng, Wenhai Huang, Xiaoliang Zheng, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112981-112981
Closed Access | Times Cited: 164
E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
Aleša Bricelj, Christian Steinebach, Robert D. Kuchta, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 158
Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
Troy A. Bemis, James J. La Clair, Michael D. Burkart
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 8042-8052
Closed Access | Times Cited: 151
The role of CDK6 in cancer
Sofie Nebenfuehr, Karoline Kollmann, Veronika Sexl
International Journal of Cancer (2020) Vol. 147, Iss. 11, pp. 2988-2995
Open Access | Times Cited: 138
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
Liguo Wang, Xuejing Shao, Tianbai Zhong, et al.
Nature Chemical Biology (2021) Vol. 17, Iss. 5, pp. 567-575
Closed Access | Times Cited: 108
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 92
Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders
Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 15, pp. 6234-6250
Open Access | Times Cited: 86
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 73
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
Yan Xiong, Yue Zhong, Hyerin Yim, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 49, pp. 22622-22632
Open Access | Times Cited: 70
Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
Matthew R. Burke, Alexis R. Smith, Guangrong Zheng
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 69
PROTACs: A novel strategy for cancer therapy
Jing Liu, Jia Ma, Yi Liu, et al.
Seminars in Cancer Biology (2020) Vol. 67, pp. 171-179
Closed Access | Times Cited: 136
Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders
Christian Steinebach, Yuen Lam Dora Ng, Izidor Sosič, et al.
Chemical Science (2020) Vol. 11, Iss. 13, pp. 3474-3486
Open Access | Times Cited: 105
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Kai Yuan, Xiao Wang, Haojie Dong, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 1, pp. 30-54
Open Access | Times Cited: 103
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang, Yujing Zhang, Yudong Wu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113749-113749
Closed Access | Times Cited: 95
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Yonghan He, Sajid Khan, Zhiguang Huo, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 92
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2
Zhihao Liu, Xi Hu, Qiwei Wang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2829-2848
Closed Access | Times Cited: 89
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality
Milka Kostić, Lyn H. Jones
Trends in Pharmacological Sciences (2020) Vol. 41, Iss. 5, pp. 305-317
Open Access | Times Cited: 74
Page 1 - Next Page

Scroll to top